Fulcrum Therapeutics, Inc. (FULC) Cash Flow Statement
Fulcrum Therapeutics, Inc. (FULC) generated -$65.8M of operating cash flow over the twelve months to 2026-06-30, spent $365000 on capital expenditure and had free cash flow of -$66.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FULCFulcrum Therapeutics, Inc.Follow FULC — free
—
Price chart with a free account
- Market cap
- 280.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -53.7 | -78.5 | -97.1 | -91.0 | -2.2 | -60.1 | -65.8 | |
| Capital expenditure | 1.3 | 1.7 | 2.0 | 0.5 | 0.3 | 0.3 | -0.4 | |
| Free cash flow | -55.0 | -80.2 | -99.0 | -91.5 | -2.5 | -60.4 | -66.1 | |
| Stock-based compensation | 7.4 | 11.1 | 13.4 | 14.8 | 14.6 | 12.5 | — |
USD millions · SEC XBRL
Fulcrum Therapeutics, Inc. — questions
- What is Fulcrum Therapeutics, Inc.'s operating cash flow?
- -$65.8M over the twelve months to 2026-06-30.
- How much does Fulcrum Therapeutics, Inc. spend on capital expenditure?
- $365000 over the twelve months to 2026-06-30.
- What is Fulcrum Therapeutics, Inc.'s free cash flow?
- -$66.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Fulcrum Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.